乌司他丁联合血必净治疗重症脓毒症的研究

目的：评估乌司他丁联合血必净注射液治疗重症脓毒症的临床疗效。方法：将符合入选标准的脓毒症患者40例，按照随机分组原则分为观察组和对照组，每组20例。所有患者给予常规抗感染治疗（根据培养结果给予敏感抗生素）和必要的对症支持治疗。观察组患者加用血必净注射液50ml静脉滴注，1次／12h，乌司他丁60万u静脉滴注，1次／12h，连用7d。记录治疗前后所有患者的体温、脉搏、呼吸、血白细胞（W33C）、降钙素原（PCT）、c反应蛋白（CRP）、急性生理学与慢性健康状况评分（APACHEII）、7天病死率。结果：疗程结束时观察组脉搏、呼吸、WBC、PCT、CRP、APACHEII评分、7天病死率均较治疗前明显下降，与对照组相比差异有统计学意义（P〈0．05）。结论：血必净注射液联合乌司他丁对重症脓毒症有明确疗效，改善临床症状，降低病死率。

Study of Ulinastatin Combined with Xuebijing in Treatmeut of Severe Sepsis

Objective： To evaluate the effectivenes ofulinastatin Combine Xuebijingin in the treatment of severe sepsis. Methods： Forty severe sepsis patients were divided into the test group and the comparison group, each of 20 patients. All patient were treated by antibiotics,symptomatic treatment and conventional nutritional support. The test group was treated by ulinastatin 600,000 U, ivd and Xuebijing 50 ml, ivd, ql2h, continue 7days. Resluts： In the end of the treatment, the many count include pulse, breath, WBC, PCT, CRP, APACHE II score and 7day mortality of the test group have more down than comparison group. Conclusion： Ulinastatin combined with Xuebijing has a good effect in the treatmeut of severe sepsis,which can improve the symptom of severe sepsis and reduce the mortality.